news

EC approves treatment for severe osteoporosis postmenopausal women

2
SHARES

Marketing authorisation has been granted by the EC for Evenity® (romosozumab) to treat osteoporosis in postmenopausal women.

The European Commission (EC) has granted marketing authorisation for Evenity® (romosozumab) for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

…[Evenity is] a new medicine that can help drive positive changes in secondary fracture prevention”

The drug is a novel bone-building monoclonal antibody (mAb) with a dual effect that increases bone formation and to a lesser extent reduces bone resorption.

Evenity is designed to work by inhibiting the activity of sclerostin, which simultaneously results in increased bone formation.

Amgen and UCB, which produce the drug, conducted a development programme that includes 19 clinical studies with approximately 14,000 patients enrolled.

“Evenity is a significant step forward in the management of osteoporosis for physicians who need to treat patients with a medicine that can rapidly increase bone mineral density within 12 months,” said Dr David Reese, Executive Vice President of R&D at Amgen. “We are pleased by the EC’s approval to make this therapy available to the millions of women at high risk of fracture in the EU.”

“With today’s approval of Evenity we can now offer patients and clinicians a new medicine that can help drive positive changes in secondary fracture prevention,” said Dr Pascale Richetta, Head of Bone and Executive Vice President, UCB.

The first launches of the drug are expected in the first half of 2020.

Share via
Share via